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Methods to efﬁciently determine the phase behavior of novel proteins have the potential to signiﬁcantly beneﬁt
structural biology efforts. Here, we present protocols to determine both the solubility boundary and the
supersolubility boundary for protein/precipitant systems using an evaporation-based crystallization platform.
This strategy takes advantage of the well-deﬁned rates of evaporation that occur in this platform to determine
the state of the droplet at any point in time without relying on an equilibrium-based end point. The dynamic
nature of this method efﬁciently traverses phase space along a known path, such that a solubility diagram can
be mapped out for both soluble and membrane proteins while using a smaller amount of protein than what
is typically used in optimization screens. Furthermore, a variation on this method can be used to decouple
crystal nucleation and growth events, so fewer and larger crystals can be obtained within a given droplet. The
latter protocol can be used to rescue a crystallization trial where showers of tiny crystals were observed. We
validated both of the protocols to determine the phase behavior and the protocol to optimize crystal quality
using the soluble proteins lysozyme and ribonuclease A as well as the membrane protein bacteriorhodopsin.
1. Introduction
Structural biology efforts are often hampered by challenges
related to protein expression, puriﬁcation, stability, and/or
crystallization.1 Here, we present an experimental approach
which has the potential to improve the rate of success associated
with obtaining crystals of sufﬁcient quality for high resolution
X-ray structure determination.2 Such screening efforts can be
viewed as a search through parameter space for regions where
phase boundaries exist between an undersaturated solution and
a saturated solution from which a crystal can grow. However,
for newly expressed and isolated proteins, the extent of this
parameter space is undeﬁned and methods to predict a priori
where such phase transitions occur do not exist.3 As a result,
such screens for suitable conditions can be time and material
intensive. Once identiﬁed, crystallization conditions typically
need to be optimized with respect to crystal quality, so that high
resolution structural information can be obtained through X-ray
analysis.1,2 Knowledge of protein phase diagrams is also
invaluable for the process of crystal quality optimization.
A phase diagram provides information about crystal nucle-
ation and growth conditions as a function of protein concentra-
tion and thermodynamic parameters such as temperature, pH,
and/or precipitant concentration. The portions of the phase
diagram associated with crystallization can be divided into three
regions. The solubility boundary separates the undersaturated
region, where any crystals present would dissolve, from the
metastable zone, where protein in solution is supersaturated and
crystals are able to grow. The supersolubility boundary separates
the metastable zone from the labile zone, where the level of
protein supersaturation is high enough to induce the nucleation
of new crystals. Thus, for a crystal to nucleate and grow, the
solution needs to reach the labile zone ﬁrst, after which it can
continue to grow in either the metastable or the labile zone.
A variety of methods to estimate the solubility boundary for
proteins have been reported.4-12 Equilibrium solubility can be
determined by probing the relationship between a crystalline
solid and the corresponding saturated solution. Typically, this
is accomplished by either dissolving crystals into an undersatu-
rated solution until saturation is reached or exposing crystals
to an oversaturated solution and allowing crystal growth to bring
the system to equilibrium. The concentration of protein in the
equilibrated mother liquor can then be assayed to determine a
point on the solubility curve. The various techniques that have
developed around these methods have typically suffered from
the need for substantial quantities of protein,4-6,12 the time to
complete an experiment,4,5,9,12 and/or the need for highly
specialized equipment.7,8 As a result, structural genomics
laboratories typically forego determination of a phase diagram,
in favor of a much less-informed “optimization” screen of phase
space. The limited supply of novel proteins outside of structural
genomics laboratories has meant that the phase behavior of only
a handful of, mostly commercially available, proteins has been
reported in detail, including lysozyme,6-22 thaumatin,23 cyto-
chrome c oxidase,24 insulin,25 chymotrypsinogen,10 glucose
isomerase,26 xylose isomerase,27 canavalin,28 concanavalin A,29
collagenase,30 photosynthetic reaction center,31 horse serum
albumin,8 ovalbumin,32,33 hemoglobin,4,5 carboxypeptidase G2,6,34
bovine pancreatic trypsin inhibitor,35 and ribonuclease A.32 More
efﬁcient methods to determine protein solubility that consume
only small amounts of precious protein sample are needed, not
only to accelerate structural biology efforts but also to improve
the scientiﬁc understanding of protein phase behavior. The
ability to rationally predict phase behavior would dramatically
reduce the need for massive screening efforts.
Though solubility is the more common thermodynamic
descriptor associated with crystallization, obtaining information
about the supersolubility boundary for proteins is much more
typical. In an optimization screen, this boundary can be
approximated by examining which conditions led to clear drops
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formed) and which conditions resulted in the formation of
crystals.36 However, the exact location of this supersolubility
boundary depends on the method and path by which supersatu-
ration is achieved.37
Methods for determining the solubility and supersolubility
curves typically require large quantities of protein because of
either the scale at which measurements must be made, as in
microcolumn measurements to locate the solubility bound-
ary,10,11,21,22 or the large number of experiments needed, as with
microbatch screens, to determine the supersolubility boundary.34,36
A key advantage of the microbatch method is the fact that the
composition of each droplet is known and that it does not vary
over time unless a phase change occurs. However, mapping out
phase behavior with the microbatch method inherently requires
selecting discrete experiments to cover phase space (an approach
which we will refer to as pixilation), thus introducing a trade-
off between the number of trials and the quality of the data.
Because of these various difﬁculties, methods for characterizing
the phase behavior of proteins that are more efﬁcient in time
and sample utilization as well as their sampling of phase space
are needed.
Once information about the phase behavior of a protein is
known, the crystallization experiment can be optimized ratio-
nally, for example, to overcome the common problems of excess
nucleation leading to many tiny crystals, and poor crystal quality.
These two issues can be avoided by separating the nucleation
and growth stages: the droplet needs to traverse a path so it
ﬁrst experiences the high levels of supersaturation needed for
nucleation (labile zone) and then experiences lower levels of
supersaturation (metastable zone) allowing for slower, more
ordered crystal growth. The various previously reported strate-
gies to decouple crystal nucleation and growth typically involve
preparation of a highly supersaturated droplet followed by a
dilution of the droplet to lower levels of supersaturation1,34,36,38-44
or the use of heterogeneous nucleants.45-50 However, without
prior knowledge of the phase diagram, ﬁnding adequate condi-
tions to decouple nucleation and growth becomes a screening
exercise of its own.
In prior work, we have introduced a controlled evaporation-
based crystallization method in which the sample equilibrates
with the ambient atmosphere rather than with a reservoir solution
(Figure 1).37,51-53 The rate of evaporation is controlled by
varying the cross-sectional area or the length of the evaporation
channel that connects the crystallization chamber with the
ambient. The major advantages of this controlled evaporation
approach over traditional vapor diffusion or microbatch methods
are that (i) a phase change is guaranteed in each experiment,
since the end point is not limited by the equilibrium imposed
by the solution present in the crystallization reservoir, (ii) the
kinetics of the experiment can be controlled through variation
of the rate of evaporation, (iii) the concentration of the sample
at any point in time can be calculated on the basis of the known,
constant evaporation rate and known initial conditions, and (iv)
the experiment can be paused at any time once promising
conditions have been reached. We have used this platform, for
example, to selectively crystallize polymorphs of glycine52 and
to determine a lower limit to the supersolubility boundary
(critical supersaturation).37
In this paper, we demonstrate the utility of our evaporation-
based crystallization platform (i) to construct the phase diagram
of a given protein/precipitant system and (ii) to optimize crystal
quality, in a much more efﬁcient manner than traditional vapor
diffusion or microbatch methods. Evaporation allows us to sample
phase space by having a limited number of droplets (typically ﬁve
different conditions repeated three times) of known composition
traverse different paths, with each experiment giving a point on
the solubility and supersolubility curves. This protocol eliminates
the need for extensive pixilation (i.e., many experiments) to fully
sample the phase space and thus reduces the amount of protein
needed. Furthermore, once the solubility and supersolubility
boundaries have been determined in this way, a dilution protocol
can be used in these same evaporation-based crystallization
platforms to decouple nucleation and growth to optimize crystal
quality. We validate these protocols using the model protein/
precipitant combinations of lysozyme/NaCl, ribonuclease A/NaCl,
and bacteriorhodopsin/NaH2PO4.
2. Experimental Methods
2.1. Evaporation-Based Crystallization Platform with
Automated Data Acquisition. The evaporation-based crystal-
lization platform used here connects the crystallization droplet
Figure 1. (a) Photograph of the automated data acquisition setup. (b) Three 16-compartment evaporation-based crystallization platforms on the
X-Y stage. The top inset shows a single crystallization compartment with a 2 µL droplet. The bottom inset shows a schematic depiction of a
crystallization compartment with the cross-sectional area (A) and evaporation channel length (L) indicated.
Determination of Protein Phase Diagrams J. Phys. Chem. B, Vol. 114, No. 13, 2010 4433with the outside environment through a channel of length L and
cross-sectional area A, which allows for gradual evaporation of
the solvent at a diffusion-limited rate. As characterized previ-
ously, the volumetric rate of evaporation of solvent from the
droplet J scales with the humidity or pressure difference ∆P
between the vapor phase around the drop and the outside
environment, and the dimensions of the evaporation channel,
speciﬁcally the ratio of A over L:37,51-53
Thus, the rate of evaporation can be regulated independently
from the composition or volume of the droplet itself by altering
the dimensions of the channel. This rate is taken to be essentially
constant because the effect of changes in the activity coefﬁcient
of the droplet with increasing concentration can be neglected
over the time scale of a crystallization experiment.51
The platforms used here were machined from poly-ether-
ether-ketone (PEEK) with 16 crystallization compartments, each
connected to the external environment by an evaporation channel
(Figure 1b). The evaporation channels used here had cross-
sectional areas A ranging from 0.3 to 1.76 mm2 and a length L
of 7 mm. The evaporation rate for each of the different channel
dimensions was determined by measuring the time for complete
evaporation of both drops of pure water and drops containing
different solutes (proteins and/or precipitants). For the solutions
used in these experiments (e.g., buffered salt solutions and
soluble proteins), the drying times for these different solutions
differed by less than 2% from that of pure water, indicating
that the decrease in water activity at the end of the drying
process has a negligible effect on the overall drying time.37,51,53
However, additives such as PEGs and detergents are known to
affect the rate of evaporation,54 necessitating separate calibration.
More information on the design, fabrication, and use of these
crystallization platforms can be found in the Supporting
Information.
Crystallization experiments in these 16-compartment plates
were tracked using an automatic, computer controlled imaging
system (Figure 1a) comprised of an optical microscope (Leica
Z16 APO) equipped with an autozoom lens (Leica 10447176),
a digital camera (Leica DFC280), and a motorized X-Y stage
(Semprex KL66). This setup uses the Advanced Acquisition
capability of Image Pro Plus (Media Cybernetics) to monitor
48 wells in autonomous fashion by sequentially moving from
well to well and capturing and storing multiple images at
different focal planes for each drop.
Using this setup, we determined the nucleation time for each
experiment with an error of (15 min. We deﬁne the nucleation
time as the time elapsed between the start of the experiment
and the ﬁrst appearance of a crystal of discernible size (∼5 µm)
in the evaporating drop. The time needed for a crystal to nucleate
and grow to this discernible size can be neglected owing to
relatively rapid crystal growth compared to typical times of
nucleation.55,56
2.2. Protein and Precipitant Solutions. Hen egg white
lysozyme (Sigma) was dissolved in 100 mM sodium acetate
buffer at pH 4.6 to obtain a protein stock solution of concentra-
tion CP ) 60 mg/mL, with an initial precipitant concentration
CS0 of NaCl (S7653, Sigma) ranging from 0.2 to 1.0 M. The
buffer solution was prepared using acetic acid and sodium
acetate (Fisher Scientiﬁc). Lysozyme concentrations were
determined by UV absorbance measurements (Hewlett-Packard
8453 UV-vis spectrophotometer) at 280 nm using an extinction
coefﬁcient of 2.64 mL/(mg-cm).57
Ribonuclease A (RNase A, R-5500, Sigma) from bovine
pancreas was dissolved in 100 mM acetate buffer at pH 4.5 to
obtain a protein stock solution of concentration CP ) 100 mg/
mL with an initial precipitant concentration CS0 of NaCl ranging
from 1.0 to 3.0 M. RNase A concentrations were determined
by absorbance measurements using an extinction coefﬁcient of
0.70 mL/(mg-cm).58
A stock solution of CP ) 24.5 mg/mL bacteriorhodopsin
solubilized in 25 mM NaH2PO4 buffer of pH 5.5 (EMD
Chemicals) with 1.2 w/v %  -octyl-D-glucoside (Anatrace) was
prepared from a culture of Halobacterium salinarium.59,60 The
NaH2PO4 buffer in this instance also serves as the precipitant.
Different initial precipitant concentrations, CS0 ) 0.025-1.015
M, were obtained by dilution with a solution of 2.5 M buffer at
pH 5.5 with 1.2 w/v %  -octyl-D-glucoside. Protein concentra-
tion was determined by absorbance measurements at 550 nm
using an extinction coefﬁcient of 58 000 M-1 cm-1.61
Prior to setting up a crystallization experiment, both the
protein and precipitant solutions were ﬁltered through 0.02 µm
(Anotop 25, Whatman), 0.1 µm (Ultrafree-MC, Millipore), or
0.22 µm (Steriﬂip, Millipore) ﬁlters. Dilutions of the protein
stock solutions with their respective buffers yielded solutions
of the same CP/CS ratio but different initial protein and
precipitant concentrations. All experiments were carried out in
a climate controlled laboratory at room temperature (23 ( 1
°C) and constant relative humidity (30 ( 2%).
Reservoir solutions for all of the proteins consisted of an
equivalent buffer solution with varying concentrations of the
precipitant and no protein present. Thus, for lysozyme and
RNase A, solutions of varying NaCl concentration in a corre-
sponding acetate buffer were used. The reservoir solution used
with bacteriorhodopsin involved varying concentrations of a
buffered NaH2PO4 solution along with 1.2 w/v %  -octyl-D-
glucoside.
2.3. Crystallization Experiments. The crystallization ex-
periments for lysozyme and RNase A were performed using
the 16-well evaporation-based crystallization platforms shown
in Figure 1. Crystal Clear tape (Hampton Research) was used
to seal the bottom of each of the individual evaporation
compartments. This tape provides transparency for viewing the
crystals and can easily be removed and replaced during the
course of an experiment. Five µL droplets of the prepared
protein solutions were pipetted onto silanized glass coverslips
(Round, D ) 18 mm, Hampton Research) and then immediately
inverted to cap and seal (high vacuum grease along the edges)
an individual evaporation compartment. More information on
the crystallization experiments can be found in the Supporting
Information.
After crystals appeared, approximately 100 µL of reservoir
solution was introduced into the compartment through the
evaporation channel via a syringe as part of the protocol to
determine the solubility boundary (see section 3 below). The
outlets of the evaporation channels were then sealed using
Crystal Clear tape. The volume of the reservoir solution was
chosen to be at least 100 µL to avoid error associated with
changes in concentration of the reservoir solution upon equili-
bration of the droplet. For each iteration of the protocol (section
3), the reservoir solutions were exchanged by ﬁrst removing
the Crystal Clear tape from the bottom and sides of the
evaporation platform, blotting away the remaining liquid, and
then resealing the bottom of the platform with fresh tape. New
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was changed in steps of 0.02 M.
Crystallization experiments for bacteriorhodopsin were per-
formed using a 96-well vapor diffusion hanging drop setup
(screw top hanging drop crystallization plate, Molecular Dimen-
sions) to demonstrate the compatibility of the protocols reported
here with this more commonly employed crystallization method.
The wells in the crystallization tray used are sealed by a screw
cap which incorporates the coverslip. The screw top allows for
repeated access to the wells without affecting the seal on the
chamber. Three µL droplets were pipetted into the recess on
these screw top coverslips which were then suspended over a
reservoir solution of at least 100 µL. The reservoir concentration
was changed over time ﬁrst to concentrate and then to dilute
the drops. The concentrations of the reservoir solutions were
changed by the addition of a more dilute or concentrated solution
rather than by iterative replacement. The concentration of the
salt solution was changed in steps of 0.025-0.1 M.
To determine a solubility boundary of a given protein/
precipitant system, the protocol explained below (section 3) was
performed for four to eight droplets of different initial composi-
tion, with each condition replicated multiple times (N ) 3-6).
The lysozyme and RNase A solubility data was well-behaved.
The error in each point on the solubility curve was taken to be
equal to the change in the reservoir concentration in the iterative
process explained below. For the bacteriorhodopsin solubility
data, error bars were calculated based off of a 95% conﬁdence
interval. The error bars associated with the supersolubility
boundary data of lysozyme and RNase A were calculated using
a 95% conﬁdence interval based on the uncertainties associated
with the slope and intercept resulting from a linear least-squares
ﬁt of the data.
3. Protocols, Experimental Results, and Discussion
Structure determination efforts of novel proteins involves ﬁrst
identiﬁcation of crystal forming conditions, followed by opti-
mization of the crystallization procedure to produce high quality
crystals suitable for X-ray analysis. Especially the identiﬁcation
of these “initial hits” is a signiﬁcant bottleneck in structural
biology efforts. While we report here speciﬁcally on protocols
to map out the phase behavior for a given crystal-forming
condition, the evaporation-based platforms used in this work
can also be used effectively to screen for initial hits, as we
discussed previously.62 Exactly as in traditional initial crystal-
lization screening approaches, a wide range of phase space can
be screened by starting with an array of droplets of different
initial composition. However, the evaporation-based approach
allows for each droplet to sample a wider range of concentrations
than is screened per droplet in equilibrium-limited approaches.
To record this additional information, the droplets need to be
monitored continuously (e.g., every 30 min) during the course
of an evaporation-based experiment, as enabled by the auto-
mated data acquisition setup (Figure 1). A ﬁrst screen using
evaporation-based platforms would hopefully yield some initial
hits, as well as preliminary information with respect to phase
behavior around those initial hits so that subsequent crystal-
lization optimization experiments can be chosen more rationally.
Following identiﬁcation of a crystal forming condition (i.e.,
an initial hit), a three-step process is used to map out both the
supersolubility and solubility boundaries for the protein as a
function of precipitant concentration. Step 1: Use evaporation
to concentrate the droplet until crystals form. This provides an
initial estimate of the supersolubility boundary. Step 2: Use
reverse vapor diffusion to slowly rehydrate the droplet until the
crystals present fully dissolve, thus determining the solubility
boundary. Step 3: Repeat step 1 for the same droplet composi-
tion at different rates of supersaturation either by starting with
dilutions of the original droplet (same CP/CS but different initial
concentrations CS0, CP0) or by using different, slower rates of
evaporation (different A/L ratio). This allows for reﬁnement of
the location of the supersolubility curve to identify a critical
supersaturation boundary above which nucleation is expected
to occur essentially instantaneously.37 These three steps are
discussed in sections 3.1, 3.2, and 3.3 below. A variation on
this method can also be used to decouple nucleation and growth
events to rescue overnucleated samples and/or improve crystal
quality, as will be discussed in section 3.4.
3.1. Step 1: Estimation of the Supersolubility Boundary.
Starting from a speciﬁed initial condition (CS0, CP0 at point 1
in Figure 2b), evaporation causes the concentration of protein
and precipitant in the droplet to increase linearly along the line
connecting the initial condition with the origin (line of constant
CP/CS).51 Because of the absence of a reservoir-associated
equilibrium state, as in vapor diffusion crystallization experi-
ments, the concentration in the droplet will continue to increase
over time until a phase change such as crystal growth occurs.
The use of automated image acquisition at regular time intervals
coupled with a known constant rate of evaporation from the
device allows for calculation of both the protein and precipitant
concentrations at any time. Given that the time it takes for a
crystal to nucleate and grow to a discernible size is negligible,55,56
the time at which a crystal is ﬁrst observed can be used to
calculate the protein and precipitant concentrations in the droplet
at this time (CS2, CP2 in Figure 2b). The state of this droplet
thus provides an estimate for the location of the supersolubility
boundary which is dependent on the rate of evaporation used.
Additional points on the supersolubility curve are determined
by performing additional experiments starting with droplets of
different protein to precipitant ratio (CP/CS), as shown in Figure
2c.
Step 1 can also be performed using a traditional vapor
diffusion platform.2 The reservoir concentration can be increased
to drive the sample to adequately high levels of supersaturation
for crystals to form. Data acquisition at regular intervals, as
needed with the evaporation-based crystallization, is not neces-
sary when using the vapor-diffusion platform. However, the
vapor-diffusion approach is potentially much slower, more labor
intensive, and potentially inaccurate because of the need to
change the reservoir concentrations repeatedly and the time
needed for equilibration.
3.2. Step 2: Determination of the Solubility Boundary.
Once crystals have formed in a droplet (Figure 2b, point 2), a
reservoir solution is introduced into the chamber, and further
evaporation is arrested by sealing the evaporation channel.
Contrary to traditional vapor diffusion, the goal of the reservoir
solution here is to slowly rehydrate the drop. Thus, a solution
with precipitant concentration that is lower than the concentra-
tion at point 2 is introduced (CS3 < CS2) and then the droplet
slowly equilibrates with the reservoir. The volume of the liquid
in the reservoir is much larger than the volume of the protein
droplet such that, when the reservoir and drop ﬁnally reach
equilibrium, the precipitant concentration in the droplet will be
equal to CS3. The concentration of protein in the solution, while
unknown due to portioning of protein between the solution and
the crystal, will equilibrate over time to a point on or close to
the solubility curve (Figure 2, point 3). Note that crystal growth
also could stop before the equilibrium condition at point 3 is
reached due to accumulation of surface defects or other factors.
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crystal, thus removing these defects and allowing the droplet
to reach the solubility boundary. During equilibration, we
monitor the droplet and we assume it to be at equilibrium when
crystal size does not change anymore. The rate at which
equilibrium is reached depends on the nature of the protein/
precipitant system. For our systems, we have observed that
equilibrium can typically be reached in less than 3 days.
Next, the reservoir solution is replaced with a more dilute
solution (CS4 < CS3) and the process of equilibration is repeated.
With each exchange of reservoir solution, the crystals in the
droplet will decrease in size, until the crystals dissolve
completely (Figure 2, point 5). At this point, the protein
concentration can be calculated because the CP/CS ratio for the
droplet is known, and the salt concentration CS in the droplet
must be equal to the salt concentration in the reservoir, CS5.
The calculated CP and the known CS ) CS5 determine a point
on the solubility boundary. Repeating this process with droplets
of different CP/CS ratios will provide additional points on the
solubility curve (Figure 2c). We used this method to obtain the
solubility boundary for the lysozyme/NaCl (Figure 3a) and
RNase A/NaCl (Figure 4a) systems. In the case of lysozyme,
solubility data is available from the literature,11,17 which is in
good agreement with our data (Figure 3a).
In a typical experiment, a ﬁrst estimate of the supersolubility
boundary can be obtained within 2-4 days. The time needed
to determine the solubility boundary depends on the number of
reservoir concentration iterations and the distance that needs to
be traversed through phase space to get to the point on the ﬁnal
solubility boundary, i.e., from point 2 to point 5 in Figure 2b.
Thus, a full determination of a phase diagram takes on the order
of 2 weeks.
Compared to the existing, microbatch- or vapor-diffusion-
based methods, the evaporation-based method to determine the
solubility and supersolubility boundaries presented here has
some key beneﬁts, most notably the fact that a single droplet
gradually traverses a path through phase space (as opposed to
discrete points, i.e., pixilation), and that the concentration of
the droplet can be calculated at any point along this path.
Researchers who are interested in obtaining phase information,
however, may not have easy access to these evaporation-based
well plates and/or an automated imaging system. Fortunately,
the above-described protocols to determine the solubility and
supersolubility boundary are also amenable to more conventional
vapor diffusion crystallization platforms, although it will be
more labor intensive than the evaporation-based approach.
The major difference between the vapor diffusion and
evaporation-based methods for determining phase behavior
occurs during step 1. Whereas a phase change is guaranteed in
the evaporation-based approach, the choice of reservoir solution
in vapor diffusion affects the end point of the trial. Furthermore,
automated imaging of directed evaporation trials provides a
reasonable estimate of the state of the droplet when crystals
ﬁrst appear. Because the chance of a vapor diffusion trial
precisely hitting an unknown end point is very low, we anticipate
two more likely scenarios: (i) the initial choice of reservoir
solution is inadequate to drive the formation of crystals and
several iterations are necessary to concentrate the droplet to the
point where crystals form, or (ii) the initial reservoir solution
results in an overshoot of the supersolubility condition, thus
requiring at best additional iterations of step 2 to ﬁnd the
solubility boundary or at worst resulting in the precipitation of
the protein in a noncrystalline form. Between these two
scenarios, the ﬁrst is preferable because of the need to identify
Figure 2. (a) Schematic depiction of the process to determine the
solubility boundary of a protein/precipitant system by evaporation (step
A) followed by an iterative reverse vapor diffusion process (steps B-D).
(b) Depiction of the process from part a in a generalized protein/precipitant
phase diagram. From the initial state (point 1), evaporation causes the
droplet to increase in concentration along the straight line connecting point
1 to the origin (constant CP/CS). Crystals nucleate and are observed at point
2 after the droplet has traversed the metastable zone and crossed the
supersolubility boundary into the labile zone. Evaporation is arrested, and
the reservoir is ﬁlled with a precipitant solution of a lower concentration
than point 2. As the droplet equilibrates with this reservoir, the concentration
of protein in solution will decrease as the crystal grows until the solubility
boundary is reached (point 3). Subsequent iterations of this process cause
the droplet to move along the solubility boundary, gradually dissolving
the protein crystal (point 4). The point at which the protein crystal has
dissolved completely (point 5) represents the point where the initial path
of the droplet ﬁrst crossed the solubility boundary. (c) Repeating the process
with droplets of different initial protein/precipitant concentration ratio (CP/
CS) allows for determination of additional points on the supersolubility
and solubility curves.
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small changes in reservoir precipitant concentration of the
droplet with multiple changes of the reservoir solution would
be the ideal way to locate the supersolubility boundary using
vapor diffusion. However, this strategy would be very labor
intensive and also slower because of the relatively low driving
force for evaporation resulting from only small changes in the
reservoir concentration. Figure 5 shows the results of this vapor
diffusion method for the determination of the solubility boundary
for the bacteriorhodopsin/NaH2PO4 system.
3.3. Step 3: Determination of the Critical Supersolubility
Boundary. In prior work, we have observed that crystals form
at progressively lower levels of supersaturation as the rate of
supersaturation is decreased. This trend ends at a critical
supersaturation where the level at which crystals are observed
becomes independent of the rate of supersaturation.37 This lower
boundary of the labile zone occurs when the rate of increase in
supersaturation is much smaller than the rate of formation of
critical nuclei. To determine a point on the critical supersolu-
bility boundary, we determined the nucleation time for a series
of droplets, each with the same CP/CS ratio, for a range of
different initial protein concentrations. From our previous work,
we know that the nucleation time and the initial protein
concentration exhibit a linear relationship for slow rates of
supersaturation.37 Direct control over the evaporation rate, and
thus over the supersaturation rate, as enabled by the platforms
used here, allows determination of the critical supersolubility
boundary with ease. Indeed, we observe this linear relationship
between nucleation time and initial protein concentration for
both systems studied here: lysozyme/NaCl (Figure 3b) and
RNase A/NaCl (Figure 4b). By extrapolating this line to the
point of zero nucleation time, we identify the CP of the point
Figure 3. (a) Solubility and critical supersolubility boundaries for lysozyme vs NaCl as obtained using an evaporation-based crystallization protocol.
The solid curves have been ﬁt through our experimental data to provide a guide for the eye. The data shows good agreement with solubility data
from the literature.11,17 (b) Nucleation time as a function of initial protein concentration for lysozyme/NaCl solutions at different CP/CS ratios used
to obtain the critical supersolubility boundary. The convergence of the various lines at a single y-intercept corresponds to the drying time for the
drop based on droplet size and evaporation rate. All data obtained at 23 °C.
Figure 4. (a) Solubility and critical supersolubility boundaries for RNase A vs NaCl as obtained using an evaporation-based crystallization
protocol. The solid curves have been ﬁt through our experimental data to provide a guide for the eye. (b) Nucleation time as a function of
initial protein concentration for RNase A/NaCl solutions at different CP/CS ratios used to obtain the critical supersolubility boundary. The
convergence of the various lines at a single y-intercept corresponds to the drying time for the drop based on droplet size and evaporation rate.
All data obtained at 23 °C.
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can then be calculated from the known CP/CS ratio. Repeating
this process with droplets of different CP/CS ratios provides
additional points on the supersolubility curve. We used this
method to obtain the critical supersolubility boundaries for the
lysozyme/NaCl and RNase A/NaCl systems, as shown in Figures
3a and 4a.
Traditional methods for determining the supersolubility
boundary, such as a grid microbatch experiment, utilize a large
number of discrete trials at speciﬁc CP and CS concentrations
to map out the phase behavior of a protein.36 The main
advantage of the microbatch method for determining the
supersolubility boundary is that the state of each droplet does
not change over time and therefore does not need to be
determined. However, the strength of the microbatch method
is also its weakness in terms of efﬁcient sample use because
many more experiments are needed to cover the phase space
than the number of experiments required in the evaporation-
based method reported here. Other methods such as vapor
diffusion, free interface diffusion, or dialysis are able to
dynamically sample a larger amount of phase space per
experiment but require equilibration before the state of the drop
(i.e., the protein and precipitant concentration) can be deter-
mined, oftentimes through separate analysis.12,26,30 In contrast
to these traditional methods to determine the supersolubility
boundary, the evaporation-based method used here can easily
sample phase space using only 15 or so droplets (i.e., ﬁve
conditions repeated three times). Starting from a set of arbitrary
initial conditions, the full extent of a phase diagram can easily
be traversed and the state of each drop (i.e., protein concentra-
tion, the presence of nuclei or not) can be determined accurately
at nearly any point in time. Unlike several of the presently used
techniques, this evaporation-based method samples a wide range
of conditions in each experiment.
3.4. Protocol for Improving Crystal Quality. Once the
phase diagram of a certain protein/precipitant system has been
determined (see section 3.3), a modiﬁcation of the evaporation-
based protocols can be used to decouple crystal nucleation and
growth, thereby effectively reducing the number of nuclei and
improving crystal size/quality (Figure 6). First, a droplet is
concentrated by evaporation until it reaches the labile zone
where nuclei form (from point 1 to point 2, Figure 6b). As soon
as crystals are observed, evaporation is arrested and a reservoir
solution of a concentration less than the concentration of the
droplet at point 2 is introduced (CS3 < CS2). Equilibration of
the droplet with this reservoir solution causes the dissolution
of many of the nuclei that had formed previously, thus
decreasing the number of small crystals present in solution. Once
equilibrium at this reservoir concentration has been reached
(point 3, Figure 6b), the reservoir is drained and the drop is
allowed to concentrate again by evaporation (step C, Figure 6b).
As long as the drop remains in the metastable region, further
evaporation will only drive growth of the few existing crystals.
Figure 5. Solubility boundary for the membrane protein bacteriorho-
dopsin vs NaH2PO4 obtained using the same protocol as before but
with a common vapor diffusion platform. The solid curve was ﬁt
through our experimental data to provide a guide for the eye. Data
obtained at 23 °C.
Figure 6. (a) Schematic depiction of the method to decouple nucleation
and growth events during evaporation-based protein crystallization (step
A) followed by reverse vapor diffusion to dissolve some nuclei (step
B), and then a second evaporation step to drive crystal growth of the
remaining nuclei (step C). (b) Graphical depiction of the process from
part a shown in reference to a generalized protein/precipitant phase
diagram. From the initial state (point 1), evaporation causes the droplet
to increase in concentration along the straight line connecting point 1
to the origin. Crystals nucleate and are observed at point 2 after the
droplet has crossed the supersolubility boundary to enter the labile zone.
Evaporation is arrested, and the reservoir is ﬁlled with a precipitant
solution of a concentration between point 2 and where the droplet
originally crossed the solubility boundary. As the droplet equilibrates
with this reservoir, the number of nuclei present in the droplet will
decrease until the solubility boundary is reached (point 3). The well is
then opened to evaporation again to allow the few remaining crystal
nuclei to grow.
4438 J. Phys. Chem. B, Vol. 114, No. 13, 2010 Talreja et al.Figure 7 shows a comparison of crystals of lysozyme, RNase
A, and bacteriorhodopsin that were grown following two
different protocols: (i) crystallization experiments where the
droplets remained in the labile zone and (ii) crystallization
experiments where the droplets traversed into the labile zone
to induce nucleation but then were guided back into the
metastable zone using the dilution protocol (Figure 6). These
experiments clearly demonstrate that use of the dilution protocol
to decouple nucleation and growth led to a smaller number of
nuclei present in solution, resulting in growth of a smaller
number of crystals of larger dimensions. Diffraction patterns
to a resolution of 1.2 and 1.12 Å for lysozyme and RNase A,
respectively, conﬁrmed the high quality of the crystals obtained
via this dilution protocol. In accordance with the literature,
crystals of the membrane protein bacteriorhodopsin obtained
via mere evaporation were of very poor quality (too small), and
not suitable for X-ray analysis.63,64 However, the dilution
protocol allows for the growth of crystals of sufﬁcient size for
harvesting, thereby making X-ray analysis possible. This latter
example of improving crystal quality highlights the promise of
the dilution method to rescue particularly challenging crystal-
lization trials.
Various strategies to decouple crystal nucleation and growth
based on traditional crystallization platforms such as microbatch
and vapor diffusion have been reported.1,34,36,38-50 For example,
Blow and co-workers started from a droplet at a concentration
where nucleation is expected in a microbatch experiment,
followed by dilution of the droplet once nuclei have formed.34
Control over the exact level of supersaturation levels in each
droplet depends on the precision by which the dilutions can be
performed, typically done using microsyringes. Chayen and co-
workers developed a protocol to decouple nucleation and growth
in vapor diffusion crystallization experiments.36 In this method,
the droplet is allowed to equilibrate over a reservoir solution
of high precipitant concentration for a period of time before
being switched over to a reservoir solution of lower concentra-
tion. In subsequent efforts, Chayen and co-workers combined
the vapor diffusion method with periodic venting of the
crystallization compartments.39-41 After the droplets have
equilibrated with the reservoir solution, the wells are vented
for short periods of time by temporarily loosening the screw
caps that hold the coverslips in place. This step intends to drive
the droplet brieﬂy into the labile zone before the solution drops
back into the metastable zone once nuclei form and start to grow.
The main drawback of this method, however, is that only a
coarse estimate can be made of the extent of solvent evaporation,
so the protein and precipitant concentrations are not precisely
known over the course of the experiment, which prevents precise
control over the desired brief venture into the labile zone.
Despite the coarseness of the rates of evaporation in these
experiments, however, Chayen and co-workers were able to
demonstrate the effectiveness of their evaporation-based strategy
with a variety of novel protein targets including the C1 domain
of cardiac myosin binding protein-C,39,40 an obesity-related
protein,40 protein PXMn,40 and R-crustacyanin,40,41 as well as
an unspeciﬁed membrane protein.40
The dilution-based protocol to decouple crystal nucleation
and growth reported here has some key advantages over these
previously reported methods to improve crystal quality. First,
execution of the protocols described in sections 3.1 and 3.3,
which require only a limited set of experiments, provides the
precise location of the solubility and supersolubility boundaries,
which enables rational design of the subsequent experiment to
decouple nucleation and growth, as introduced in this section.
Starting from appropriate initial conditions and evaporation rate,
the droplet will only venture brieﬂy into the labile zone, such
that a few nuclei form while excessive nucleation is avoided.
In contrast, the strategies reported for microbatch and vapor
diffusion only allow for relatively coarse control over the path
into the labile zone and the length of time the droplet remains
in this zone, thus hampering control over the extent of
nucleation. In addition, these experiments are often conducted
without knowledge of the phase diagram, thus transforming the
identiﬁcation of adequate conditions to decouple nucleation and
growth into an entire screening exercise of its own.
Second, while the traditional vapor diffusion strategies have
the potential to “rescue” otherwise clear droplets by driving the
droplet past its equilibrium end point and hopefully into the
labile zone, droplets cannot be rescued from the common
occurrence of excessive nucleation using previously reported
approaches. In contrast, the method to decouple crystal nucle-
ation and growth reported here allows experiments that exhibit
excessive nucleation to be rescued, as exempliﬁed by our results
with bacteriorhodopsin (Figure 7c).
Third, the evaporation-based protocol introduced here pro-
vides control not only over the end point of each experiment
but also over the rate of increase in supersaturation while the
droplet resides in the metastable zone, which can have a
Figure 7. Optical micrographs comparing the results from evaporation-
based crystallization experiments (a1, b1, c1) to those using the dilution
protocol to decouple nucleation and growth (a2, b2, c2) for three
different protein/precipitant systems: (a) lysozyme/NaCl starting from
CP0 ) 16 mg/mL, CS0 ) 0.32 M; (b) RNase A/NaCl starting from CP0
) 60 mg/mL, CS0 ) 2 M; and (c) bacteriorhodopsin/NaH2PO4 starting
from CP0 ) 17.2 mg/mL, CS0 ) 0.025 M.
Determination of Protein Phase Diagrams J. Phys. Chem. B, Vol. 114, No. 13, 2010 4439profound effect on the number, quality, and size of crystals.51
While traditional methods such as vapor diffusion provide some
control over the rate of supersaturation in a crystallizing droplet,
precise control over these rates is difﬁcult because they vary
nonlinearly with time.54,65 Control over the rate of supersatu-
ration in the evaporation-based platforms here is straightforward,
and is linear with time, thus allowing for more ordered growth
of crystals.
4. Conclusions
While screening for crystallization conditions is a relatively
high throughput exercise, the platform and methods presented
here provide a way to make more efﬁcient use of each droplet
in a trial. Speciﬁcally, we introduced and validated protocols
for (i) the determination of protein/precipitant phase diagrams
and (ii) the decoupling of crystal nucleation and growth to
enhance crystal size and quality. The ﬁrst set of protocols
provides an efﬁcient method for estimating the solubility and
critical supersolubility boundaries for a protein/precipitant
system (sections 3.1-3.3). Because the critical supersolubility
boundary is determined, the phase information is unbiased by
dynamics of the crystallization experiment, thus enabling cross
platform comparison of phase behavior data, provided that also
the second method has been performed such that dynamic/
kinetic effects have been minimized.
The second set of protocols reported here is geared toward
improving crystal quality (section 3.4). Determining the phase
behavior of a protein/precipitant system using the ﬁrst set of
protocols enables the rational design of subsequent experiments
to decouple nucleation and growth. Appropriate initial conditions
and evaporation rates can be selected such that a droplet ventures
only brieﬂy into the labile zone before being guided back into
the metastable zone, resulting in fewer, larger, and higher quality
crystals. This dilution protocol is not only a way of rescuing
drops with excessive nucleation but could also be used to try
and reverse aggregation. Moreover, rather than abandoning clear
drops, evaporation is a means to further concentrate a sample
and thus query a wider range of phase space, potentially
identifying crystallization conditions that would have been
otherwise missed. These strategies along with the accumulation
of knowledge concerning protein phase behavior will help to
advance protein crystallization efforts from an art to a science.
These protocols exploit the ability of the evaporation-based
crystallization platforms to traverse phase space more efﬁciently
and in a more controlled fashion than in the traditional methods
based on microbatch or vapor-diffusion platforms. While the
evaporation-based crystallization platforms are not commercially
available at present, they can be easily manufactured using the
drawings provided in the Supporting Information. Their opera-
tion requires the same general laboratory supplies (e.g., pipettes,
coverslips) as the more traditional platforms do. Looking ahead,
transitioning from the microliter-scale 16-well evaporation
platforms that are ﬁlled using micropipets to a nanoliter-scale
microﬂuidic platform with a larger number of wells while
affording fully automatic ﬁlling and operation would further
enhance the protocols presented here with respect to the efﬁcient
use of sample while also decreasing times for equilibration.
Alternative microﬂuidic platforms for determining the phase
behavior of small molecules and polymer phases have already
demonstrated the efﬁcacy of this approach, though this technol-
ogy has yet to be applied to protein systems.44,66,67
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